ChitogenX Inc. (CHNXF)
- Previous Close
0.0354 - Open
0.0400 - Bid --
- Ask --
- Day's Range
0.0354 - 0.0354 - 52 Week Range
0.0350 - 0.1228 - Volume
40,000 - Avg. Volume
1,116 - Market Cap (intraday)
2.792M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date May 29, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
www.chitogenx.comRecent News: CHNXF
Performance Overview: CHNXF
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHNXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHNXF
Valuation Measures
Market Cap
2.02M
Enterprise Value
4.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-247.42%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.26M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
111k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.01M
Research Analysis: CHNXF
Company Insights: CHNXF
CHNXF does not have Company Insights